<p>Celldex Therapeutics（納斯達克股票代碼：CLDX - 獲取免費報告）在週三發佈的一份報告中，巴克萊的股票研究分析師將其目標價從 21.00 美元上調至 24.00 美元，Benzinga 報道。該券商目前對這家生物製藥公司的股票給予 “減持” 評級。巴克萊的目標價意味着該公司股價可能下跌 9.62%。</p>
<p>獲取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
<p>其他一些分析師最近也對該股票發表了評論。Canaccord Genuity Group 在 9 月 17 日的報告中重申了對 Celldex Therapeutics 的 “買入” 評級，並給出了 62.00 美元的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Celldex Therapeutics 的 “賣出（d-）” 評級。HC Wainwright 在 8 月 20 日的報告中將 Celldex Therapeutics 的目標價從 50.00 美元下調至 42.00 美元，並給予該公司 “買入” 評級。瑞穗證券在 10 月 21 日的研究報告中開始覆蓋 Celldex Therapeutics 的股票，給予 “跑贏大盤” 評級和 48.00 美元的目標價。最後，花旗集團在 8 月 20 日的報告中將 Celldex Therapeutics 的目標價從 56.00 美元下調至 48.00 美元，並給予該公司 “買入” 評級。一位股票研究分析師對該股票給予了強烈買入評級，七位給予買入評級，一位給予持有評級，兩位給予賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價為 44.10 美元。</p>
<p><strong>查看我們對 Celldex Therapeutics 的最新股票分析</strong></p>
<h2>Celldex Therapeutics 股價下跌 0.5%</h2>
<p>納斯達克 CLDX 在週三下跌 0.13 美元，報 26.56 美元。該股票交易量為 190,756 股，而其平均交易量為 993,017 股。該公司的市值為 17.6 億美元，市盈率為-7.86，貝塔值為 1.13。該股票的 50 日移動平均線為 26.38 美元，200 日移動平均線為 24.00 美元。Celldex Therapeutics 的 12 個月低點為 14.40 美元，12 個月高點為 30.50 美元。</p>
<p>Celldex Therapeutics（納斯達克股票代碼：CLDX - 獲取免費報告）最後一次公佈季度財報是在 11 月 10 日，生物製藥公司報告每股收益（EPS）為-1.01 美元，低於市場共識預期的-0.88 美元，差距為 0.13 美元。Celldex Therapeutics 的股本回報率為-33.22%，淨利潤率為-3,446.88%。整體來看，股票研究分析師預計 Celldex Therapeutics 在本年度的每股收益將為-2.48 美元。</p>
<h2>Celldex Therapeutics 的內部活動</h2>
<p>在相關消息中，內部人士 Richard M. Wright 於 11 月 13 日星期四出售了 49,298 股該公司的股票。股票以平均價格 24.00 美元出售，總交易額為 1,183,152.00 美元。交易後，該內部人士直接持有該公司 20,833 股，價值約 499,992 美元。此次交易使其持股比例減少了 70.29%。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。公司內部人士目前持有 4.40% 的股份。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者和對沖基金最近調整了對該股票的持有。Aster Capital Management DIFC Ltd 在第三季度購買了 Celldex Therapeutics 的新股份，價值約 26,000 美元。Nisa Investment Advisors LLC 在第二季度將其在 Celldex Therapeutics 的股份增加了 171.7%。Nisa Investment Advisors LLC 目前持有 1,394 股該生物製藥公司的股票，價值 28,000 美元，此前在上個季度增持了 881 股。Wilmington Savings Fund Society FSB 在第三季度購買了 Celldex Therapeutics 的新股份，價值 42,000 美元。Russell Investments Group Ltd.在第二季度將其在 Celldex Therapeutics 的持股增加了 27.6%。Russell Investments Group Ltd.目前持有 2,315 股該生物製藥公司的股票，價值 47,000 美元，此前在上個季度增持了 501 股。最後，Quantbot Technologies LP 在第三季度購買了 Celldex Therapeutics 的新頭寸，價值約 63,000 美元。</p>
<h2>Celldex Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Celldex Therapeutics, Inc 是一家生物製藥公司，專注於開發用於治療各種疾病的單克隆抗體和雙特異性抗體。其藥物候選者包括用於治療炎症、過敏、自身免疫及其他嚴重疾病的抗體基礎治療。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好五隻股票，勝過 Celldex Therapeutics</li>
<li>資產配置：成功投資組合的關鍵。您關注自己的投資組合嗎？</li>
<li>英特爾以低價收購人工智能技術</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>隨着下一次計算革命的展開，值得關注的四隻量子股票</li>
<li>安靜期到期的解釋</li>
<li>工業領域的大規模突破：現在必須關注的三隻股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Celldex Therapeutics 嗎？</h2>
<p>在您考慮 Celldex Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買，而 Celldex Therapeutics 並不在名單上。</p>
<p>雖然塞德斯醫療目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

塞德斯醫療

<p>巴克萊將 Celldex Therapeutics（NASDAQ:CLDX）的目標價從 21.00 美元上調至 24.00 美元，維持 “減持” 評級。新的目標價暗示與前一交易日收盤價相比有 9.62% 的潛在下行空間。其他分析師的評級不一，普遍評級為 “適度買入”，目標價為 44.10 美元。Celldex 最近報告了季度虧損，內部人士 Richard M. Wright 出售了股份。機構投資者已調整了對該公司的持股</p>

<p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) had its price target boosted by equities research analysts at Barclays from $21.00 to $24.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an &#34;underweight&#34; rating on the biopharmaceutical company's stock. Barclays's price target points to a potential downside of 9.62% from the company's previous close.</p>
<div class="lb-trans"><p>Celldex Therapeutics（納斯達克股票代碼：CLDX - 獲取免費報告）在週三發佈的一份報告中，巴克萊的股票研究分析師將其目標價從 21.00 美元上調至 24.00 美元，Benzinga 報道。該券商目前對這家生物製藥公司的股票給予 “減持” 評級。巴克萊的目標價意味着該公司股價可能下跌 9.62%。</p>
</div><p>Get <strong>Celldex Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
</div><p>A number of other analysts also recently commented on the stock. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Mizuho began coverage on shares of Celldex Therapeutics in a research report on Tuesday, October 21st. They set an &#34;outperform&#34; rating and a $48.00 target price for the company. Finally, Citigroup reduced their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $44.10.</p>
<div class="lb-trans"><p>其他一些分析師最近也對該股票發表了評論。Canaccord Genuity Group 在 9 月 17 日的報告中重申了對 Celldex Therapeutics 的 “買入” 評級，並給出了 62.00 美元的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Celldex Therapeutics 的 “賣出（d-）” 評級。HC Wainwright 在 8 月 20 日的報告中將 Celldex Therapeutics 的目標價從 50.00 美元下調至 42.00 美元，並給予該公司 “買入” 評級。瑞穗證券在 10 月 21 日的研究報告中開始覆蓋 Celldex Therapeutics 的股票，給予 “跑贏大盤” 評級和 48.00 美元的目標價。最後，花旗集團在 8 月 20 日的報告中將 Celldex Therapeutics 的目標價從 56.00 美元下調至 48.00 美元，並給予該公司 “買入” 評級。一位股票研究分析師對該股票給予了強烈買入評級，七位給予買入評級，一位給予持有評級，兩位給予賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價為 44.10 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Celldex Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Celldex Therapeutics 的最新股票分析</strong></p>
</div><h2>Celldex Therapeutics Trading Down 0.5%</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 股價下跌 0.5%</h2>
</div><p>NASDAQ CLDX traded down $0.13 on Wednesday, hitting $26.56. 190,756 shares of the stock traded hands, compared to its average volume of 993,017. The company has a market capitalization of $1.76 billion, a P/E ratio of -7.86 and a beta of 1.13. The stock has a 50-day moving average of $26.38 and a 200 day moving average of $24.00. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $30.50.</p>
<div class="lb-trans"><p>納斯達克 CLDX 在週三下跌 0.13 美元，報 26.56 美元。該股票交易量為 190,756 股，而其平均交易量為 993,017 股。該公司的市值為 17.6 億美元，市盈率為-7.86，貝塔值為 1.13。該股票的 50 日移動平均線為 26.38 美元，200 日移動平均線為 24.00 美元。Celldex Therapeutics 的 12 個月低點為 14.40 美元，12 個月高點為 30.50 美元。</p>
</div><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. As a group, equities research analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>Celldex Therapeutics（納斯達克股票代碼：CLDX - 獲取免費報告）最後一次公佈季度財報是在 11 月 10 日，生物製藥公司報告每股收益（EPS）為-1.01 美元，低於市場共識預期的-0.88 美元，差距為 0.13 美元。Celldex Therapeutics 的股本回報率為-33.22%，淨利潤率為-3,446.88%。整體來看，股票研究分析師預計 Celldex Therapeutics 在本年度的每股收益將為-2.48 美元。</p>
</div><h2>Insider Activity at Celldex Therapeutics</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 的內部活動</h2>
</div><p>In related news, insider Richard M. Wright sold 49,298 shares of the business's stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. The trade was a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 4.40% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Richard M. Wright 於 11 月 13 日星期四出售了 49,298 股該公司的股票。股票以平均價格 24.00 美元出售，總交易額為 1,183,152.00 美元。交易後，該內部人士直接持有該公司 20,833 股，價值約 499,992 美元。此次交易使其持股比例減少了 70.29%。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。公司內部人士目前持有 4.40% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd bought a new stake in shares of Celldex Therapeutics in the third quarter worth about $26,000. Nisa Investment Advisors LLC boosted its stake in Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 881 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics in the third quarter worth $42,000. Russell Investments Group Ltd. raised its holdings in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 501 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Celldex Therapeutics during the third quarter valued at approximately $63,000.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該股票的持有。Aster Capital Management DIFC Ltd 在第三季度購買了 Celldex Therapeutics 的新股份，價值約 26,000 美元。Nisa Investment Advisors LLC 在第二季度將其在 Celldex Therapeutics 的股份增加了 171.7%。Nisa Investment Advisors LLC 目前持有 1,394 股該生物製藥公司的股票，價值 28,000 美元，此前在上個季度增持了 881 股。Wilmington Savings Fund Society FSB 在第三季度購買了 Celldex Therapeutics 的新股份，價值 42,000 美元。Russell Investments Group Ltd.在第二季度將其在 Celldex Therapeutics 的持股增加了 27.6%。Russell Investments Group Ltd.目前持有 2,315 股該生物製藥公司的股票，價值 47,000 美元，此前在上個季度增持了 501 股。最後，Quantbot Technologies LP 在第三季度購買了 Celldex Therapeutics 的新頭寸，價值約 63,000 美元。</p>
</div><h2>Celldex Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc 是一家生物製藥公司，專注於開發用於治療各種疾病的單克隆抗體和雙特異性抗體。其藥物候選者包括用於治療炎症、過敏、自身免疫及其他嚴重疾病的抗體基礎治療。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Celldex Therapeutics</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Intel Snaps Up AI Tech for Pennies on the Dollar</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>4 Quantum Stocks to Watch as the Next Computing Revolution Unfolds</li>
<li>Quiet Period Expirations Explained</li>
<li>Massive Breakout in Industrials: 3 Must-Watch Stocks Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好五隻股票，勝過 Celldex Therapeutics</li>
<li>資產配置：成功投資組合的關鍵。您關注自己的投資組合嗎？</li>
<li>英特爾以低價收購人工智能技術</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>隨着下一次計算革命的展開，值得關注的四隻量子股票</li>
<li>安靜期到期的解釋</li>
<li>工業領域的大規模突破：現在必須關注的三隻股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CLDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Celldex Therapeutics 嗎？</h2>
</div><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Celldex Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買，而 Celldex Therapeutics 並不在名單上。</p>
</div><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然塞德斯醫療目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

巴克萊將塞德斯醫療（NASDAQ:CLDX）的目標股價上調至 24.00 美元